Widespread dips in sales, particularly in Europe, after consumers stopped pandemic-driven stockpiling of OTC drugs and nutritional products, and the removal of OTC allergy Zantac in the US took big chunks out of Sanofi’s consumer health care sales in its latest quarter.
However, the boost to the French pharma’s consumer health sales from Xyzal Allergy 24HR’s launch as the first OTC product...



